DrugPatentWatch Database Preview
SYMPAZAN Drug Profile
When do Sympazan patents expire, and when can generic versions of Sympazan launch?
Sympazan is a drug marketed by Aquestive Therap and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and thirty-six patent family members in eighteen countries.
The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the clobazam profile page.
Summary for SYMPAZAN
| International Patents: | 136 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SYMPAZAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SYMPAZAN |
| DailyMed Link: | SYMPAZAN at DailyMed |
Recent Litigation for SYMPAZAN
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Aquestive Therapeutics, Inc. v. Biodelivery Sciences International, Inc. | 2018-10-30 |
| INDIVIOR INC. v. DR. REDDY'S LABORATORIES S.A. | 2017-09-14 |
| MONOSOL RX, LLC v. BIODELIVERY SCIENCES INTERNATIONAL, INC. | 2017-09-14 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Dr. Reddy’s Laboratories, Inc. | 2017-06-12 |
| Par Pharmaceutical, Inc. | 2017-06-09 |
| Mylan Technologies, Inc. | 2016-11-04 |
US Patents and Regulatory Information for SYMPAZAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therap | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Aquestive Therap | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Aquestive Therap | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Aquestive Therap | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Aquestive Therap | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SYMPAZAN
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011143424 | Start Trial |
| Australia | 2011253023 | Start Trial |
| Canada | 2473970 | Start Trial |
| Australia | 2010214780 | Start Trial |
| Australia | 2018205083 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
